Skip to main content
OpenTrials
Completed

NCT Number: NCT03741270

Safety of Rabivax-S for Pre-exposure Prophylaxis

People who are at frequent or continuous risk of exposure to rabies virus should be vaccinated against the disease (pre-exposure prophylaxis). This includes people who work with rabies virus in research or diagnostic laboratories or vaccine production facilities, veterinarians, staff, animal-control and wildlife workers in areas where rabies is endemic. Veterinary students in clinical placements and externships are included in this category. Currently, DVM students at Ross University School of Veterinary Medicine (RUSVM) are vaccinated against rabies in their 7th semester (final pre-clinical semester). Vaccinations are done by RUSVM Health Services using Rabivax-S, produced by the Serum Institute of India (study co-sponsors). Previously-unvaccinated students receive three injections of vaccine, on day 0, 7 and 21-28. The aim of the study is to generate additional data on safety and tolerability of Rabivax-S administered as pre-exposure prophylaxis to this population.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Rabies Vaccine Adverse Reaction

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Ross University School of Veterinary Medicine

Basseterre, Saint Kitts and Nevis

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

A DVM student registered at RUSVM will be eligible for inclusion in the study if the student is:

  • in the 7th semester of the DVM program, or
  • is in the 5th or 6th semester of the DVM program and is planning to undertake a veterinary externship in the following semester break that would require pre-exposure prophylaxis to rabies.

Exclusion criteria

A DVM student who meets the inclusion criteria will be excluded from the study if the student:

  • has previously received a dose of rabies vaccine, or
  • has any condition for which rabies vaccination is contra-indicated, or
  • does not provide informed consent for participation.

Treatment and study plan

Rabivax-S

Biological

Rabivax-S is a lyophilized vaccine manufactured by Serum Institute of India Pvt. Ltd. containing inactivated purified rabies antigen (Pitman Moore, PM3218 as virus strain) produced using Vero ATCC CCL 81 cells. The diluent (sterile water for injection) is provided in a separate 1 mL ampoule. After reconstitution, a single dose of 1 mL contains an inactivated, purified rabies antigen (not less than 2.5 IU), glycine (40 mg), sucrose (40 mg) and human serum albumin (25% 10 mg). The intervention is administered by intramuscular injection of 1 mL reconstituted vaccine in the deltoid area of the upper arm, on days 0, 7 and 21 (or 28).

Primary outcomes

  1. Number of participants with at least one solicited adverse event (AE) within 4 days after any dose

    Time frame: Through 4 days after each dose

    Based on the package insert for Rabivax-S, the following adverse events will be solicited:

    • Local reactions (limited to the site of the injection): pain, erythema, oedema, pruritus and induration.
    • Systemic reactions: fever, shivering, malaise, asthenia, faintness, dizziness, headache, myalgia, arthralgia, nausea and abdominal pain.
    • Hypersensitivity or allergic reactions: anaphylaxis, urticaria, rash and erythema multiforme.

Secondary outcomes

  1. Number of unsolicited adverse events during 28 days after the first dose

    Time frame: Through 28 days after the first dose given (day 0)

    Definitions of AEs and SAEs are taken from the OHRP's Guidance on Reviewing and Reporting Unanticipated Problems Involving Risks to Subjects or Others and Adverse Events.

    AE means any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the subject's participation in the research, whether or not considered related to the subject's participation in the research.

    A SAE is any AE temporally associated with the subject's participation in research that meets any of the following criteria:

    • results in death;
    • is life-threatening;
    • requires inpatient hospitalization;
    • results in a persistent or significant disability/incapacity;
    • results in a congenital anomaly/birth defect; or
    • any other AE that, based upon appropriate medical judgment, may jeopardize the subject's health and may require medical or surgical intervention to prevent one of the other outcomes listed in this definition.

  2. Number of serious adverse events during 28 days after the first dose

    Time frame: Through 28 days after the first dose given (day 0)

  3. Number of participants with at least one solicited adverse event (AE) within 4 days after first dose

    Time frame: Through 4 days after first dose (days 0-3)

  4. Number of participants with at least one solicited adverse event (AE) within 4 days after second dose

    Time frame: Through 4 days after second dose (days 7-10)

  5. Number of participants with at least one solicited adverse event (AE) within 4 days after third dose

    Time frame: Through 4 days after second dose (days 21-24 or days 28-31)

Sponsors and collaborators

Lead sponsor

Ross University School of Veterinary Medicine

Other

Collaborators

  • Serum Institute of India Pvt. Ltd.

Registry information

Official study title

Safety of Rabivax-S in Individuals Receiving Pre-exposure Prophylaxis (PrEP)

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Nov 14, 2018
Registry last updated
Sep 24, 2019

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.